Xuelin Dou, Chunrui Li, Aijun Liao, Yafei Wang, Zhongjun Xia, Jing Liu, Hong Cen, Yan Xu, Fei Li, Tadao Ishida, Yuping Zhong, Satoshi Ito, Togano Tomiteru, Baijun Fang, Chunyan Sun, Hongmei Jing, Masaki Ri, Toshiyuki Kitano, Kazutaka Sunami, Chihiro Shimazaki, Shigeki Ito, Jie Jin, Rong Fu, Takuya Komeno, Kosei Matsue, Shang-Yi Huang, Sikander Ailawadhi, Florence Suzan Teisserenc, Dan Gao, Xu Wang, Yi Li, Gang Liu, Jin Lu. "Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study." Blood, 2025. doi:10.1182/blood-2025-5819